Apolipoprotein E fragment (133-149) – COG133: acetyl-LRVRLASHLRKLRKRLL-NH2 (CAS : 514200-66-9) SB-PEPTIDE offers Apolipoprotein E (ApoE) mimetic peptide COG133 – LRVRLASHLRKLRKRLL – which competes with the ApoE holoprotein for binding the low density lipoprotein (LDL) receptor. Apolipoprotein E (ApoE): A key player in lipid transport and beyond Apolipoprotein E (apoE) is a low-density lipoprotein (LDL) receptor ligand that belongs to the family of fat-binding proteins, known as apolipoproteins. While the liver and macrophages primarily produce ApoE in peripheral tissues to mediate cholesterol metabolism, in the central nervous system (CNS), astrocytes take the lead in producing ApoE. ApoE plays a vital role in lipid transport, facilitating the movement of lipids such as fats, cholesterol, and fat-soluble vitamins between organs via plasma and interstitial fluids. In the central CNS, it serves as a crucial cholesterol carrier, promoting neuron survival, sprouting, and exhibiting functional anti-inflammatory and neuroprotective effects.Beyond its role in lipid transport, ApoE binds to a diverse range of cellular receptors, influencing immune responses, promoting cell migration, and potentially impacting transcription regulation.With its multifaceted functions, ApoE stands as a cornerstone in maintaining plasma and tissue lipid homeostasis and orchestrating complex interplays within the body. ApoE(133-149) mimetic peptide : COG 133 COG 133 mimetic peptide, takes the incredible capabilities of acting the same way as the LDL receptor-binding domain of ApoE. Therefore, this peptide wields a non-competitive stance against the alpha-7 nicotinic acetylcholine receptor, which is not only implicated in long-term memory but also in neurotoxicity, stroke, myocardial infarction, sepsis, Alzheimer’s disease, cancer progression, and angiogenic/neurogenic activity. Moreover, COG133’s anti-apoptotic effects further accentuate its potential.By mimicking ApoE, COG 133 / ApoE(133-149) masterfully inhibits the NMDA receptor channel function through interactions with the low-density lipoprotein receptor-related protein. The peptide emerged as a potent agent in reducing inflammation, cellular infiltration, and demyelination, making strides in animal models of multiple sclerosis (MS) and the 5-fluorouracil model of intestinal mucositis.Indeed, COG-133 emerged as a champion to suppress symptoms of experimental autoimmune encephalomyelitis (EAE), curbing inflammation, demyelination, and cell infiltration in the spinal cord. ApoE (133-149) fragment additionally showcased its prowess by decreasing TNF-α and nitric oxide (NO) release in BV-2 microglia and counteracting LPS-induced increases in brain levels of TNF-α and IL-6 in mice. The peptide also stands as a guardian of hippocampal neuronal health and offers promise in delaying disease onset and reducing severity of EAE mouse model. COG-133 applications The applications of COG 133 (ApoE 133-149) resonate across diverse fields of research and healthcare.Generally speaking, COG133’s multifaceted influences on inflammation, cellular responses, and neuronal health open doors to novel therapies for neurological disorders.Its potential as a groundbreaking tool in understanding and combating MS holds the promise of improved treatments and enhanced quality of life for patients suffering from this particular disease.SB-PEPTIDE is proud to offer this remarkable peptide for neurological research!
575.95RON
În stoc
Număr Catalog 466-SB180CategorieAfaceri și industrie > Știință și laboratorFurnizorSmartox BiotechnologyGentaurDimensiune1Tipsingle
